CD163 and neoplasm: Additionally, anti‐PD‐L1 administration may trigger the accumulation of immunosuppressive M2 macrophages in tumor sites characterized by the “M2” markers CD163 and PD‐L1 in different cancers, including NCSLC, colorectal cancer, breast cancer, and cervical cancer,126, 127, 128, 129 and this macrophage accumulation may worsen the prognosis during ICB treatment.